{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T05:08:23Z","timestamp":1755839303930,"version":"3.40.5"},"reference-count":32,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Glucose\u20106\u2010phosphate dehydrogenase (G6PD) deficiency, the most common enzymopathy in humans, can cause acute haemolysis resulting from exposure to certain medications, chemicals, infections and fava beans. Rasburicase, used to manage elevated uric acid levels in the oncologic emergency of tumour lysis syndrome, is one such drug. The US Food and Drug Administration (FDA) recommends testing of G6PD status prior to rasburicase administration for patients at higher risk for G6PD deficiency.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective chart review of all oncology patients for whom a semi\u2010quantitative biochemical test for detecting G6PD deficiency was performed prior to rasburicase administration over a 2.5\u2010year period, in a large academic metropolitan hospital.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 16 out of 260 tested individuals as G6PD\u2010deficient (6.1%), including six females. On average, test results were electronically available to health care providers within 4\u00a0hours of sample collection, with most results available within 2\u20133\u00a0hours. Four G6PD\u2010deficient patients developed elevated uric acid levels. Two of the G6PD\u2010deficient patients were treated with rasburicase, and subsequently developed haemolysis, which was appropriately managed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In summary, by providing information about G6PD status with a rapid turnaround time, we have taken a significant step towards personalized medicine in our institution. In spite of the test implementation, two out of four G6PD\u2010deficient patients, who were no longer candidates for rasburicase use, still received the drug, highlighting the need for improved provider education.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15353","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T08:33:24Z","timestamp":1649925204000},"page":"4163-4170","source":"Crossref","is-referenced-by-count":5,"title":["Impact of pre\u2010emptive rapid testing for glucose\u20106\u2010phosphate dehydrogenase deficiency prior to rasburicase administration at a tertiary care centre: A retrospective study"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2834-0843","authenticated-orcid":false,"given":"Mythily","family":"Ganapathi","sequence":"first","affiliation":[{"name":"Department of Pathology &amp; Cell Biology Columbia University Irving Medical Center  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NewYork\u2010Presbyterian Hospital Columbia University Irving Medical Center  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4422-2882","authenticated-orcid":false,"given":"Kenneth","family":"Ofori","sequence":"additional","affiliation":[{"name":"Department of Pathology &amp; Cell Biology Columbia University Irving Medical Center  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vimla","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Pathology &amp; Cell Biology Columbia University Irving Medical Center  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard O.","family":"Francis","sequence":"additional","affiliation":[{"name":"Department of Pathology &amp; Cell Biology Columbia University Irving Medical Center  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kratz","sequence":"additional","affiliation":[{"name":"Department of Pathology &amp; Cell Biology Columbia University Irving Medical Center  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2008.12.005"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/376246a0"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201003\u2010416032"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000944"},{"key":"e_1_2_11_6_1","unstructured":"US Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling.http:\/\/www.fda.gov\/Drugs\/ScienceResearch\/ResearchAreas\/Pharmacogenetics\/ucm083378.htm. Accessed April 22 2022."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C336"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000058"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551\u20106776\u201022.6.471"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574886312666170111151246"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21462"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omu053"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp150591"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013501996"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12350"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000351048"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23182"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211429385"},{"key":"e_1_2_11_20_1","unstructured":"Elitek [drug label].Bridgewater NJ: Sanofi\u2010Aventis US.http:\/\/dailymed.nlm.nih.gov\/. Accessed February 10 2018."},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1590\/0074\u20100276140123"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41397\u2010018\u20100043\u20103"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13513"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12857"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G272"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.2004.05094.x"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15537"},{"issue":"4","key":"e_1_2_11_28_1","first-page":"179","article-title":"Laboratory turnaround time","volume":"28","author":"Hawkins RC","year":"2007","journal-title":"Clin Biochem Rev"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihy060"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002224"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116063"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1373\/jalm.2017.024935"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010020\u201074200\u2010y"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15353","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15353","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T11:52:59Z","timestamp":1692618779000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/bcp.15353"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15353","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2022,5,2]]}}}